Download PDF
Semin Neurol 2005; 25(2): 217-228
DOI: 10.1055/s-2005-871330
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Chronic Inflammatory Demyelinating Polyneuropathy and Other Immune-Mediated Demyelinating Neuropathies

Richard A. Lewis1
  • 1Wayne State University School of Medicine, Detroit, Michigan.
Further Information

Publication History

Publication Date:
03 June 2005 (online)

    Permissions and Reprints

ABSTRACT

The identification of specific disorders caused by immune-mediated attack on Schwann cells and myelin have both improved and confused our understanding and classification of chronic inflammatory and immune-mediated neuropathies. Some investigators consider all neuropathies that respond to immunosuppressive treatment as chronic inflammatory demyelinating polyneuropathy (CIDP), regardless of whether there is evidence for demyelination. Other investigators rely on a very strict definition of CIDP and do not include variations. The goal of this article is to clarify the spectrum of these disorders and provide a logical classification scheme that has clinical utility and yet allows for new information that might distinguish new variations. Therapeutic strategies are also discussed.

KEYWORDS

CIDP (chronic inflammatory demyelinating polyneuropathy) - myelin-associated glycoprotein - CANOMAD (chronic ataxic neuropathy, ophthalmoplegia, IgM paraproteinemia, cold agglutinins, and disialosyl antibodies) - paraprotein - MMN (multifocal motor neuropathy) - Lewis-Sumner syndrome - multifocal acquired demyelinating sensory and motor (neuropathy) - paraprotein - conduction block

REFERENCES

  • 1 Dyck P J, Lais A C, Ohta M et al.. Chronic inflammatory demyelinating polyradiculoneuropathy.  Mayo Clin Proc. 1975;  50 621-637
    PubMedGoogle Scholar
  • 2 Haq R U, Pendlebury W W, Fries T J, Tandan R. Chronic inflammatory demyelinating polyradiculoneuropathy in diabetic patients.  Muscle Nerve. 2003;  27 465-470
    CrossrefPubMedGoogle Scholar
  • 3 Sharma K R, Cross J, Farronay O, Ayyar D R, Shebert R T, Bradley W G. Demyelinating neuropathy in diabetes mellitus.  Arch Neurol. 2002;  59 758-765
    CrossrefPubMedGoogle Scholar
  • 4 Gorson K C, Ropper A H, Adelman L S, Weinberg D H. Influence of diabetes mellitus on chronic inflammatory demyelinating polyneuropathy.  Muscle Nerve. 2000;  23 37-43
    CrossrefPubMedGoogle Scholar
  • 5 Krendel D A, Costigan D A, Hopkins L C. Successful treatment of neuropathies in patients with diabetes mellitus.  Arch Neurol. 1995;  52 1053-1061
    PubMedGoogle Scholar
  • 6 Ad Hoc Subcommittee of the American Academy of Neurology Task Force . Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP).  Neurology. 1991;  41 617-618
    PubMedGoogle Scholar
  • 7 Saperstein D S, Katz J S, Amato A A, Barohn R J. The clinical spectrum of chronic acquired demyelinating polyneuropathy.  Muscle Nerve. 2001;  24 311-324
    CrossrefPubMedGoogle Scholar
  • 8 Hughes R, Bensa S, Willison H et al.. Randomized controlled trial of intravenous immunoglobulin versus oral prednisone in chronic inflammatory demyelinating polyradiculoneuropathy.  Ann Neurol. 2001;  50 195-201
    CrossrefPubMedGoogle Scholar
  • 9 Magda P, Latov N, Brannagan III T H, Weimer L H, Chin R L, Sander H W. Comparison of electrodiagnostic abnormalities and criteria in a cohort of patients with chronic inflammatory demyelinating polyneuropathy.  Arch Neurol. 2003;  60 1755-1759
    CrossrefPubMedGoogle Scholar
  • 10 Gorson K G, Allam G, Ropper A H. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy.  Neurology. 1997;  48 321-328
    CrossrefPubMedGoogle Scholar
  • 11 Rotta F T, Sussman A T, Bradley W G, Ram Ayyar D, Sharma K R, Shebert R T. The spectrum of chronic inflammatory demyelinating polyneuropathy.  J Neurol Sci. 2000;  173 129-139
    CrossrefPubMedGoogle Scholar
  • 12 Kaku D A, England J D, Sumner A J. Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paraglobiside.  Brain. 1994;  117 941-947
    PubMedGoogle Scholar
  • 13 Katz J S, Saperstein D S, Gronseth G, Amato A A, Barohn R J. Distal acquired demyelinating symmetric neuropathy.  Neurology. 2000;  54 615-620
    CrossrefPubMedGoogle Scholar
  • 14 Willison H J, O’Leary C P, Veitch J et al.. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-diasialosyl IgM antibodies.  Brain. 2001;  124 1968-1977
    CrossrefPubMedGoogle Scholar
  • 15 Willison H J, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies.  Brain. 2002;  125 2591-2625
    CrossrefPubMedGoogle Scholar
  • 16 Lopate G, Choksi R, Pestronk A. Severe sensory ataxia and demyelination polyneuropathy with IgM anti-GM2 and GalNAc-GD1A antibodies.  Muscle Nerve. 2002;  25 828-836
    PubMedGoogle Scholar
  • 17 Soubrier M J, Dubost J J, Sauvezie B JM. POEMS syndrome: a study of 25 cases and a review of the literature.  Am J Med. 1994;  97 543-553
    CrossrefPubMedGoogle Scholar
  • 18 Katz J S, Barohn R J, Kojan S et al.. Axonal multifocal motor neuropathy without conduction block or other features of demyelination.  Neurology. 2002;  58 615-620
    PubMedGoogle Scholar
  • 19 Parry G J, Clarke S. Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease.  Muscle Nerve. 1988;  11 103-107
    CrossrefPubMedGoogle Scholar
  • 20 Pestronk A, Cornblath D R, Ilyas A A et al.. A treatable multifocal neuropathy with antibodies to GM1 ganglioside.  Ann Neurol. 1988;  24 73-78
    CrossrefPubMedGoogle Scholar
  • 21 Chad D A, Hammer K, Sargent J. Slow resolution of multifocal weakness and fasciculation: a reversible motor neuron syndrome.  Neurology. 1982;  32 958-964
    CrossrefPubMedGoogle Scholar
  • 22 Engel W K, Hopkins L C, Rosenberg B J. Fasciculating progressive muscular atrophy (F-PMA) remarkably responsive to antidysimmune treatment (ADIT): a possible clue to more ordinary ALS?.  Neurology. 1985;  335(suppl 1b) 72
    PubMedGoogle Scholar
  • 23 Freddo L, Yu R K, Latov N et al.. Gangliosides GM1 and GD1b are antigens for IgM M-protein in a patient with motor neuron disease.  Neurology. 1986;  36 454-458
    PubMedGoogle Scholar
  • 24 Roth G, Rohr J, Magistris M R, Oschner F. Motor neuropathy with proximal multifocal persistent block, fasciculations and myokymia. Evolution to tetraplegia.  Eur Neurol. 1986;  25 416-423
    CrossrefPubMedGoogle Scholar
  • 25 Bouche P, Moulonguet A, Ben Younes-Chennnoufi A et al.. Multifocal motor neuropathy with conduction block: a study of 24 patients.  J Neurol Neurosurg Psychiatry. 1995;  59 38-44
    CrossrefPubMedGoogle Scholar
  • 26 Comi G, Amadio S, Galardi G, Fazio R, Nemni R. Clinical and neurophysiological assessment of immunoglobulin therapy in five patients with multifocal motor neuropathy.  J Neurol Neurosurg Psychiatry. 1994;  57(suppl) 35-37
    PubMedGoogle Scholar
  • 27 Leger J-M, Younes-Chennoufi A B, Chassande B et al.. Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy.  J Neurol Neurosurg Psychiatry. 1994;  57(suppl) 46-49
    PubMedGoogle Scholar
  • 28 Lange D J, Trojaberg W, Latov N et al.. Multifocal motor neuropathy with conduction block: is it a distinct clinical entity?.  Neurology. 1992;  42 497-505
    PubMedGoogle Scholar
  • 29 Oh S J, Kim D E, Kuruguolu H R. What is the best diagnostic index of conduction block and temporal dispersion?.  Muscle Nerve. 1994;  17 489-493
    PubMedGoogle Scholar
  • 30 Chaudhry V, Cornblath D R, Griffin J W et al.. Multifocal motor neuropathy: electrodiagnostic features.  Muscle Nerve. 1994;  17 198-205
    PubMedGoogle Scholar
  • 31 American Association of Electrodiagnostic Medicine . Consensus criteria for the diagnosis of partial conduction block.  Muscle Nerve. 1999;  22 S225-S229
    PubMedGoogle Scholar
  • 32 Katz J S, Wolfe G I, Bryan W W, Jackson C E, Amato A A, Barohn R J. Electrophysiologic findings in multifocal motor neuropathy.  Neurology. 1997;  48 700-707
    CrossrefPubMedGoogle Scholar
  • 33 Pakiam A S, Parry G J. Multifocal motor neuropathy without overt conduction block.  Muscle Nerve. 1998;  21 243-245
    PubMedGoogle Scholar
  • 34 Weimer L H, Grewal R P, Lange D J. Electrophysiologic abnormalities other than conduction block in multifocal motor neuropathy.  Muscle Nerve. 1994;  9 A1089
    PubMedGoogle Scholar
  • 35 Van den Berg L H, Franssen H, Van Doorn P A, Wokke J H. Intravenous immunoglobulin treatment in lower motor neuron disease associated with highly raised anti-GM1 antibodies.  J Neurol Neurosurg Psychiatry. 1997;  63 674-677
    PubMedGoogle Scholar
  • 36 Azulay J P, Blin O, Pouget J et al.. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo controlled study.  Neurology. 1994;  44 429-432
    PubMedGoogle Scholar
  • 37 Tsai C P, Lin K P, Liao K K et al.. Immunosuppressive treatment in lower motor neuron syndrome with autoantibodies against GM1.  Eur Neurol. 1993;  33 446-449
    PubMedGoogle Scholar
  • 38 Olney R K, Lewis R A, Putnam T D, Campellone Jr J V. Consensus criteria for the diagnosis of multifocal motor neuropathy.  Muscle Nerve. 2003;  27 117-121
    CrossrefPubMedGoogle Scholar
  • 39 Kaji R, Shibasaki H, Kimura J. Multifocal demyelinating motor neuropathy: cranial nerve involvement and immunoglobulin therapy.  Neurology. 1992;  42 506-509
    CrossrefPubMedGoogle Scholar
  • 40 Kaji R, Oka N, Tsuji T et al.. Pathological findings at the site of conduction block in multifocal motor neuropathy.  Ann Neurol. 1993;  33 152-158
    CrossrefPubMedGoogle Scholar
  • 41 Kaji R, Kimura J. Facts and fallacies on anti-GM1 antibodies: physiology of motor neuropathies.  Brain. 1999;  122 797-798
    CrossrefPubMedGoogle Scholar
  • 42 Ogawa-Goto K, Funamoto N, Abe T et al.. Different ceramide compositions of gangliosides between human motor and sensory nerves.  J Neurochem. 1990;  55 1486-1493
    PubMedGoogle Scholar
  • 43 Sheikh K A, Deerinck T J, Ellisman M H, Griffin J W. The distribution of ganglioside-like moieties in peripheral nerves.  Brain. 1999;  122 449-460
    CrossrefPubMedGoogle Scholar
  • 44 Takigawa T, Yasuda H, Kikkawa R, Shigeta Y, Saida T, Kitasato H. Antibodies against GM1 ganglioside affect K+ and Na+ currents in isolated rat myelinated nerve fibers.  Ann Neurol. 1995;  37 436-442
    CrossrefPubMedGoogle Scholar
  • 45 Waxman S G. Sodium channel blockade by antibodies: a new mechanism of neurological disease?.  Ann Neurol. 1995;  37 421-423
    CrossrefPubMedGoogle Scholar
  • 46 Pestronk A, Choksi R. Multifocal motor neuropathy. Serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates.  Neurology. 1997;  49 1289-1292
    PubMedGoogle Scholar
  • 47 Van Schaik I N, Bossuyt P M, Brand A, Vermeulen M. Diagnostic value of GM1 antibodies in motor neuron disorders and neuropathies: a meta-analysis.  Neurology. 1995;  45 1570-1577
    PubMedGoogle Scholar
  • 48 Carpo M, Allaria S, Scarlato G, Nobile-Orazio E. Anti-GM1 IgM antibodies in multifocal motor neuropathy: slightly improved detection with covalink ELISA technique.  Neurology. 1999;  53 2206-2207
    PubMedGoogle Scholar
  • 49 Santoro M, Uncini A, Corbo M et al.. Experimental conduction block induced by serum from a patient with anti-GM1 antibodies.  Ann Neurol. 1992;  31 385-390
    CrossrefPubMedGoogle Scholar
  • 50 Van den Berg L H, Kerkhoff H, Oey P L et al.. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulin: a double blind, placebo controlled study.  J Neurol Neurosurg Psychiatry. 1995;  59 248-252
    CrossrefPubMedGoogle Scholar
  • 51 Federico P, Zochodne D W, Hahn A F, Brown W F, Feasby T E. Multifocal motor neuropathy improved by IVIg. Randomized, double-blind, placebo-controlled study.  Neurology. 2000;  55 1256-1262
    CrossrefPubMedGoogle Scholar
  • 52 Léger J-M, Chassande B, Musset L, Meininger V, Bouche P, Bauman N. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind placebo-controlled study.  Brain. 2001;  124 145-153
    CrossrefPubMedGoogle Scholar
  • 53 Van den Berg L H, Franssen H, Wokke J HJ. The long term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy.  Brain. 1998;  121 421-428
    CrossrefPubMedGoogle Scholar
  • 54 Azulay J-Ph, Rihet P, Pouget J et al.. Long term follow up of multifocal motor neuropathy with conduction block under treatment.  J Neurol Neurosurg Psychiatry. 1997;  62 391-394
    PubMedGoogle Scholar
  • 55 Meucci N, Cappellari A, Barbieri S, Scarlato G, Nobile-Orazio E. Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy.  J Neurol Neurosurg Psychiatry. 1997;  63 765-769
    CrossrefPubMedGoogle Scholar
  • 56 Van den Berg-Vos R M, Franssen H, Wokke J HJ, Van den Berg L H. Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment.  Brain. 2002;  125 1875-1886
    CrossrefPubMedGoogle Scholar
  • 57 Nobile-Orazio E, Meucci N, Carpo M et al.. Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block.  J Neurol Neurosurg Psychiatry. 2002;  72 761-766
    CrossrefPubMedGoogle Scholar
  • 58 Van den Berg-Vos R M, Franssen H, Wokke J HJ, Van Es H V, Van den Berg L H. Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin.  Ann Neurol. 2000;  48 919-926
    CrossrefPubMedGoogle Scholar
  • 59 Van den Berg-Vos R M, Franssen H, Visser J et al.. Disease severity in multifocal motor neuropathy and its association with the response to immunoglobulin treatment.  J Neurol. 2002;  249 330-336
    PubMedGoogle Scholar
  • 60 Pestronk A, Lopate G, Kornberg A J et al.. Distal lower motor neuron syndrome with high-titer serum IgM anti-GM1 antibodies: improvement following immunotherapy with monthly plasma exchange and intravenous cyclophosphamide.  Neurology. 1994;  44 2027-2031
    PubMedGoogle Scholar
  • 61 Pestronk A. Multifocal motor neuropathy: diagnosis and treatment.  Neurology. 1998;  51(suppl 5) S22-S24
    PubMedGoogle Scholar
  • 62 Lewis R A, Sumner A J, Brown M J, Asbury A K. Multifocal demyelinating neuropathy with persistent conduction block.  Neurology. 1982;  32 958-962
    CrossrefPubMedGoogle Scholar
  • 63 Saperstein D S, Amato A A, Wolfe G I et al.. Multifocal acquired demyelinating sensory and motor neuropathy: the Lewis-Sumner syndrome.  Muscle Nerve. 1999;  22 560-566
    CrossrefPubMedGoogle Scholar
  • 64 Van den Berg-Vos R M, Van den Berg L H, Franssen H et al.. Multifocal inflammatory demyelinating neuropathy: a distinct clinical entity?.  Neurology. 2000;  54 26-32
    CrossrefPubMedGoogle Scholar
  • 65 Oh S J, Claussen G C, Kim D S. Motor and sensory demyelinating mononeuropathy multiplex (multifocal motor and sensory demyelinating neuropathy): a separate entity or a variant of chronic inflammatory demyelinating polyneuropathy.  J Peripher Nerv Syst. 1997;  2 362-369
    PubMedGoogle Scholar
  • 66 Viala K, Renié L, Maisonobe T et al.. Follow-up study and response to treatment in 23 patients with Lewis-Sumner syndrome.  Brain. 2004;  127 2010-2017
    CrossrefPubMedGoogle Scholar
  • 67 Nikhar N J, Lewis R A. Multifocal sensorimotor demyelinating neuropathy with persistent conduction block is distinct from multifocal motor neuropathy.  Neurology. 1998;  50(suppl) A206
    PubMedGoogle Scholar
  • 68 Parry G J. Are multifocal motor neuropathy and Lewis-Sumner syndrome distinct nosologic entities?.  Muscle Nerve. 1999;  22 557-559
    PubMedGoogle Scholar
  • 69 Lewis R A. Relationship of multifocal motor neuropathy and Lewis-Sumner syndrome.  Muscle Nerve. 1999;  23 1738-1739
    PubMedGoogle Scholar
  • 70 Barhon R J, Kissel J T, Warmolts J R, Mendell J R. Chronic inflammatory demyelinating polyradiculoneuropathy.  Arch Neurol. 1989;  46 878-884
    CrossrefPubMedGoogle Scholar

Richard A LewisM.D. 

Department of Neurology, Wayne State University School of Medicine

4201 Saint Antoine Street, Health Center 6E

Detroit, MI 48201-2153

      >